Wulbrand et al (1998) found the c-Met mRNA expression frequencies to vary considerably, with the highest found in gastrinomas (33%) and the lowest (11%) in small intestine carcinoid tumours. In a gastrinoma study (Peghini et al, 2002), universal expression of c-Met mRNA was demonstrated in all 22 tumours investigated. Compared to normal pancreas, only a minority of the tumours (14%) showed slight overexpression of c-Met. Unlike findings in other tumour types (Maulik et al, 2002), c-Met overexpression in these gastrinomas were not correlated with a more aggressive tumour behaviour. The gene discussed is MET; the disease is digestive system neuroendocrine neoplasm.